文献速递免疫规划传染病防控与疫情报告

SARS-CoV-2灭活疫苗在印尼18-59岁健康成人中的III期随机对照试验中期分析

A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.
PubMed 文献 · Vaccine · 2021-09-24

该研究为在印尼开展的随机、双盲、安慰剂对照III期试验,共纳入1620名18-59岁健康成人,按0、14天程序接种2剂灭活SARS-CoV-2疫苗或安慰剂。中期分析显示,疫苗预防有症状确诊COVID-19的效力为65.30%,安全性良好,免疫原性方面ELISA法IgG阳转率97.48%、中和试验阳转率87.15%。

要点

  • 灭活SARS-CoV-2疫苗对有症状确诊COVID-19的效力为65.30%。
  • ELISA法IgG阳转率97.48%,中和试验阳转率87.15%。
  • 多数不良反应为征集性且程度轻微,注射部位疼痛最常见。

核心结论

  • 3个月中期分析显示,该灭活疫苗预防COVID-19的效力为65.30%,安全性和免疫原性良好。

研究设计与样本

  • 随机、双盲、安慰剂对照III期试验,1620名18-59岁健康成人按0、14天程序接种2剂疫苗或安慰剂。
  • 中期分析纳入免疫原性亚组540人的安全性和免疫原性数据,以及1620名受试者的效力分析。

主要发现

  • 多数不良反应为征集性且程度轻微,注射部位疼痛最常见。
  • ELISA法检测IgG阳转率为97.48%,中和试验阳转率为87.15%。
  • 第二剂后至少14天,预防有症状确诊COVID-19的效力为65.30%。

临床怎么用

  • 该灭活疫苗可用于18-59岁健康成人预防有症状COVID-19,采用0、14天2剂程序。
  • 接种后需关注注射部位疼痛等轻微征集性不良反应。

局限性

  • 本文为3个月中期分析,长期效力与安全性数据尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The WHO declared COVID-19 a pandemic on March 11th, 2020. This serious outbreak and the precipitously increasing numbers of deaths worldwide necessitated the urgent need to develop an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The development of COVID-19 vaccines has moved quickly. In this study, we assessed the efficacy, safety, and immunogenicity of an inactivated (SARS-CoV-2) vaccine. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to evaluate the efficacy, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine and its lot-to-lot consistency. A total of 1620 healthy adults aged 18-59 years were randomly assigned to receive 2 injections of the trial vaccine or placebo on a day 0 and 14 schedule. This article was based on an interim report completed within 3 months following the last dose of study vaccine. The interim analysis includes safety and immunogenicity data for 540 participants in the immunogenicity subset and an efficacy analysis of the 1620 subjects. For the safety evaluation, solicited and unsolicited adverse events were collected after the first and second vaccination within 14 and 28 days, respectively. Blood samples were collected for an antibody assay before and 14 days following the second dose. RESULTS: Most of the adverse reactions were in the solicited category and were mild in severity. Pain at the injection site was the most frequently reported symptom. Antibody IgG titer determined by enzyme-linked immunosorbent assay was 97.48% for the seroconversion rate. Using a neutralization assay, the seroconversion rate was 87.15%. The efficacy in preventing symptomatic confirmed cases of COVID-19 occurring at least 14 days after the second dose of vaccine using an incidence rate was 65.30%. CONCLUSIONS: From the 3-month interim analysis, the vaccine exhibited a 65.30% efficacy at preventing COVID-19 illness with favorable safety and immunogenicity profiles.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fadlyana E, Rusmil K, Tarigan R, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia. Vaccine. 2021. PMID: 34620531. doi:10.1016/j.vaccine.2021.09.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。